Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author holds a long position in SDGR.

← Back to Free Index

SDGR

Analysis as of: 2026-10-28

Schrödinger, Inc.

Schrödinger sells computational chemistry and molecular discovery software, and also monetizes its platform through drug discovery collaborations and proprietary programs.

ai biotech enterprise healthcare software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Workflow Proof Matters More Than Scientific Promise

The upside case is a cleaner, more valuable software model, not a heroic drug pipeline bet. If hosted renewals, Bunsen, and workflow pricing become repeatable, Schrödinger can compound into a stronger discovery infrastructure asset.

Analysis

Thesis

Over five years, Schrödinger can evolve from expert simulation software into a broader discovery operating layer: hosted delivery, Bunsen, workflow embedment, and selective downstream economics should expand wallet share faster than reported revenue noise suggests today.

Last Economy Alignment

Cheaper cognition and better AI increase the amount of molecular work done in software, and Schrödinger owns validated workflow control points. It is helped by AI, but not immune to pricing pressure if orchestration becomes generic.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

2.4x (from 5 most recent analyses)

Reasoning

This is a credible 2x-3x setup, not a moonshot. The upside does not require a major proprietary drug win; it mainly requires hosted transition noise to clear, large accounts to expand ACV, and Bunsen plus adjacent modules to shift value capture from specialist seats toward governed workflow and throughput.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The main risk is weak value capture, not scientific irrelevance. Schrödinger must prove that hosted delivery, Bunsen, and adjacent workflow tools become repeatable, diversified, and economically durable across the customer base. If that proof arrives, the stock can rerate; if not, the company may stay important to customers while remaining a noisy, concentrated, mid-growth asset.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

No new official disclosure in the last 7-10 days materially changed the core thesis; the story remains centered on software proof rather than pipeline surprise.
The next major gating event is now immediate: third-quarter 2026 results are scheduled for November 4, 2026.
Late-October share strength increased near-term expectations, which makes the next earnings reaction more two-sided.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.40

They control trusted software that helps drug teams decide what molecules to design and test, so AI should push more research activity onto their system. The risk is that customers may use fewer paid users or build their own agent layer, so Schrödinger must charge for governed workflow and verified results, not just access.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$25.86

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research